Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Metabolomics Reveals Changes in CSF in Model of HIV Dementia
6 June 2008. A scan of cerebrospinal fluid from simian immunodeficiency virus (SIV)-infected monkeys turned up potential markers of central nervous system disease. The report, from Gary Siuzdak and Howard Fox of the Scripps Research Institute in La Jolla, California, shows the potential of metabolomics, a comprehensive cataloguing of small molecules, to yield biomarkers for CNS conditions, possibly including Alzheimer disease and other neurodegenerative disorders. The work appears in the June 2 online edition of the Journal of Clinical Investigation.

In humans, HIV infection of the CNS can lead to cognitive complications including dementia, but the pathophysiology of that damage is not well understood. In the current study, first author William Wikoff, along with Gurudutt Pendyala, Siuzdak, and Fox, used a monkey model of HIV infection to look for clues to the process. They performed a mass spectrometry analysis of CSF from four monkeys before infection, shortly after infection, and at sacrifice one to four months after infection. For the study, they chose monkeys with symptoms of CNS involvement.

Of 3,687 different components they identified in the CSF, 142 (4 percent) changed more than 1.5-fold after infection. Most of the metabolites that changed (97 percent) increased with infection. Eleven of these metabolites were identified as carnitines, acyl-carnitines, fatty acids, and phospholipids. The changes were markers of CNS infection, and not general SIV infection, because the same metabolites were not altered in infected animals without signs of CNS involvement.

The observed increase in fatty acids and phospholipids could be due to either pathological processes like phospholipase C activation, or to breakdown of the blood-brain barrier. Both factors may be at work, the results suggested. Measurements of mRNA for two phospholipases confirmed increased levels in the monkeys’ brains. In addition, all of the monkeys showed evidence of compromised blood-brain barrier.

In AD, CSF proteins have received the most attention as biomarkers so far. A decrease in Aβ peptides and an increase in phosphorylated tau indicate an increased risk of conversion to dementia (see ARF related news story). In the metabolite arena, Fox and colleagues cite two older papers indicating that neither carnitine nor acyl-carnitine levels in CSF correlate with AD (Rubio et al., 1998), and that a decrease—rather than an increase—in CSF fatty acids concentration was seen in AD (Mulder et al., 1998). Thus, changes in metabolomic profiles are likely distinct in different CNS diseases, and the authors conclude that, “Similar studies in other neurodegenerative as well as neuropsychiatric disorders have the potential to address the physiological disruptions underlying CNS diseases.”—Pat McCaffrey.

Reference:
Wikoff WR, Pendyala G, Siuzdak G, Fox HS. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest. 2008 Jun 2. [Epub ahead of print] Abstract

 
Comments on News and Primary Papers
  Comment by:  Jungsu Kim
Submitted 8 June 2008  |  Permalink Posted 16 June 2008

In this study, Wikoff et al. utilized non-biased metabolomics approaches to investigate CSF metabolome changes in SIV-infected monkeys. The authors reported that the levels of several specific carnitines, fatty acids, and lysophosphatidylcholines were increased in the infected monkeys with encephalitis, possibly due to the upregulation of PLAs and the breakdown of BBB. This report is an exemplar of applying the methodology developed in Dr. Siuzdak’s lab (i.e., XCMS) to neuroscience. Certainly, the current study elegantly demonstrates the enormous potential of metabolomics for the discovery of novel biomarkers and pathogenic pathways in neurodegenerative disorders.

However, the study also reveals the limitation of current technologies. Although hundreds of distinct features were observed, only 12 metabolites were identified and the identities of 11 metabolites were confirmed by using Q-TOF. To overcome such limitation, high resolution FT-MS/MS or high sensitivity capillary NMR studies are warranted to identify other unknown metabolites, which may lead to the discovery of novel...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad